Document:

Exhibit 10.19

 

 

Cognition Therapeutics Inc.

2403 Sidney Street

Pittsburgh PA 15203

t: 412 481 2210 f: 412 481 2216

 

www.cogrx com

 

October 7, 2019

 

Mr. James O’Brien

20 Hollow Tree Ridge Road

Darien, Connecticut 06820

 

Dear Jim:

 

This letter agreement (the
 “Agreement”) sets forth the terms and conditions of your employment with Cognition Therapeutics, Inc., a Delaware corporation
(the “Company”).

 

1.            Position
and Duties.

 

(a)            Position.
Effective October 28, 2019 (the “Start Date”), you shall commence your employment with the Company as its Chief Financial
Officer. This Agreement will set forth the terms and conditions of your employment in such capacity.

 

(b)            Duties.
Your employment by the Company shall be full-time and exclusive of any other employment and you shall devote all of your business time,
attention and services to the Company and its Affiliates (as defined below). You will perform such duties as may be customary to, and
consistent with, the position of Chief Financial Officer, and such duties that may reasonably be assigned from time to time by the Chief
Executive Officer. You will devote your best efforts, business judgment, skill and knowledge to the advancement of the business and interests
of the Company and to the discharge of your duties and responsibilities to the Company. Notwithstanding the foregoing, during the term
of your employment, you may participate in charitable activities and manage your passive investments, in each case so long as such activities
do not interfere with the performance of your duties and responsibilities hereunder or present a conflict of interest with the Company
or its Affiliates.

 

(c)            Office
Location. You shall perform your services hereunder primarily at the Company’s offices to be established in the Tri-State (New
York, New Jersey, Connecticut) area, and in Pittsburgh, PA, subject to reasonable business travel.

 

2.            Compensation
and Benefits. During your employment, as compensation for all services performed by you for the Company, the Company will provide
you the following pay and benefits:

 

(a)            Base
Salary. The Company will pay you a base salary (the “Base Salary”) at the rate of $340,000 per year, payable in accordance
with the regular payroll practices of the Company and subject to adjustment from time to time by the Company’s Board of Directors
(the “Board”) in its discretion.

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Two

 

(b)            Bonus
Compensation. During your employment, you will be considered annually for a cash bonus targeted at 30% of your Base Salary. The amount
of any bonus awarded to you for any year will be determined by the Board in its discretion, based on your performance and that of the
Company against the specific priorities and/or goals established for each such annual period by the Board. Any annual bonus will be paid
in the year following the fiscal year with respect to which such annual bonus was earned and attributable, at the same time as other executives
receive any applicable bonus compensation and as soon as practicable following the availability of the Company’s results of operations
for the applicable fiscal year. Subject to Section 5(a)(i), in order for you to receive payment of any such annual bonus, you must
be employed by the Company on the date of payment.

 

(c)            Stock
Options. In connection with the commencement of your employment, the Company’s management will recommend that the Board grant
you a stock option (the “Option”), under and subject in all respects to the Cognition Therapeutics 2017 Equity Incentive Plan
(the “Plan”) and award agreement, to purchase the number of shares of the Company’s common stock, par value $0.001 per
share (the “Common Stock”) equal to 0.75% of the Company’s outstanding equity on a fully diluted basis. The Option will:
(A) have an exercise price per share equal to the fair market value per share of Common Stock on the date of the grant, as determined
by the Board; and (B) will be subject to vesting requirements such that (i) 25% of the shares of Common Stock underlying the
Option shall vest as of the first anniversary of the Start Date, and (ii) the remaining 75% of the shares of Common Stock underlying
the Option shall vest in 36 substantially equal monthly installments as of the last day of each month thereafter, in each case if you
remain continuously employed by the Company through the applicable vesting dates; provided, however, that any then-unvested portion
of the Option shall vest upon the closing of a Change in Control (as defined in Section 6) if you remain employed through such event.

 

(d)            Participation
in Employee Benefit Plans. You shall be eligible to participate in any and all employee benefit plans from time to time in effect
for employees of the Company generally. The Company shall not be required to establish or maintain any such program or plan. Such participation
shall be subject to (i) the terms of the applicable plan documents, and (ii) generally applicable Company policies. The Company
may alter, modify, add to or terminate its employee benefit plans at any time as it, in its sole discretion, determines to be appropriate.

 

(e)            Paid
Time Off. You will be entitled to 4 weeks vacation, in addition to holidays observed by the Company, pursuant to the Company’s
paid-time-off policies. Vacation may be taken at such times and intervals as you shall determine, subject to the business needs of the
Company and prior notice to the Chief Executive Officer.

 

(f)            Business
Expenses. The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the performance of
your duties and responsibilities for the Company, subject to any maximum annual limit and other restrictions on such expenses set forth
by the Company and to such reasonable substantiation and documentation as the Company may specify from time to time.

 

3.            Confidential
Information; Restricted Activities; Intellectual Property. To induce the Company to enter into this Agreement, as a condition to
your employment by the Company, and in recognition of (i) the compensation payable to you pursuant to this Agreement, and
(ii) such other consideration payable to you by the Company or any of its Affiliates, you must sign and return to the 

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Three

 

Company
no later than your Start Date the Confidential Disclosure, Invention Assignment, Noncompetition, Non-Solicitation and
Non-Interference Agreement attached hereto as Exhibit A (the “Restrictive Covenants Agreement”).

 

4.            Termination
of Employment. Your employment under this Agreement shall continue for no definite term until terminated pursuant to this Section 4.

 

(a)            The
Company may terminate your employment for Cause upon notice to you setting forth in reasonable detail the nature of the Cause (as defined
below). The following, as determined by the Company in its reasonable judgment, shall constitute “Cause” for termination:
(i) your persistent and willful refusal to follow reasonable directives of the Chief Executive Officer; (ii) gross negligence
or willful misconduct in the performance of your duties and responsibilities to the Company or any of its Affiliates; (iii) your
material breach of this Agreement or any other agreement between you and the Company, which breach continues for more than 15 days after
the Company gives you written notice that sets forth in reasonable detail the nature of such breach; or (iv) other conduct by you
that is or could reasonably anticipated to be materially harmful to the business, interests or reputation of the Company or any of its
Affiliates. The Company may terminate your employment as a result of your Disability and at any time other than for Cause upon notice
to you. Termination of your employment as a result of your Disability will not be construed as a termination by the Company “other
than for Cause.”

 

(b)            You
may terminate your employment at any time upon 60 days’ notice to the Company without Good Reason. You may also terminate your employment
with Good Reason. “Good Reason” means, without your consent: (i) a material diminution by the Company of your responsibilities
with the position you then hold, or (ii) the Company reduces your Base Salary, other than in connection with the same percentage
across-the-board decrease in base salaries applicable to other key executives; provided that, in each case, written notice of your resignation
for Good Reason must be delivered to the Company within thirty (30) days after the occurrence of the event falling within the definition
of Good Reason in order for your resignation for Good Reason to be effective, the Company fails to cure such event within thirty (30)
days after delivery of such notice to cure any such event and you resign your employment within thirty (30) days following the expiration
of that cure period.

 

(c)            This
Agreement shall automatically terminate in the event of your death during employment.

 

5.            Severance
Payments and Other Matters Related to Termination.

 

(a)            Involuntary
Termination/Good Reason Termination.

 

 (i)            In
the event of termination of your employment by the Company other than for Cause, or your resignation of employment for Good Reason,
the Company (or its successor, as applicable) will (A) continue to pay you your Base Salary for a period of six (6) months
after the date of termination; (B) pay you for any bonus to which you would have otherwise been entitled for the prior fiscal
year but for the termination of your employment prior to payment of such bonus; and (C) waive the applicable premium otherwise
payable for COBRA continuation coverage for you (and, to the extent covered immediately prior to the date of such cessation, your
eligible dependents) for a period equal to six (6) months following termination; provided, however, that if such termination
occurs within eighteen (18)

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Four

 

 months after your Start Date, the Base Salary continuation described in subsection (A), and the
subsidized COBRA coverage described in subject (C), shall be provided for nine (9) months in lieu of six (6) months. The
Company will also pay you any Base Salary earned but not paid through the date of termination, pay for any vacation time accrued but
not used to that date and reimburse any business expenses incurred in accordance with Company policy and subject to the
Company’s policies regarding appropriate documentation (the “Accrued Rights”).

 

 (ii)            Notwithstanding
the foregoing, in the event your employment is terminated by the Company (or its successor) other than for Cause or by you for Good Reason,
in each case during the twelve (12) month period immediately following the occurrence of a Change in Control (as defined below), you will
receive the payments and benefits described in Section 5(a)(i) above, subject to the following modifications: (A) references
in in Section 5(a)(i) to “six (6) months” or “nine (9) months” (as applicable) will each be
replaced with a reference to “twelve (12) months”; and (B) all unvested restricted stock, stock options and other equity
incentives awarded to you by the Company will become immediately and automatically fully vested and exercisable (as applicable). The payments
described in subsection (A) of this Section 5(a)(ii) shall be paid in a lump sum not later than the forty-fifty (45th)
day following your termination of employment.

 

(b)            Limitation
of Payments. If any payment or benefit due under this Agreement, together with all other payments and benefits you receive or are
entitled to receive from the Company or any of its Affiliates, would (if paid or provided) constitute an excess parachute payment (within
the meaning of Section 280G(b)(1) of the Code), the amounts otherwise payable and benefits otherwise due under this Agreement will
be limited to the minimum extent necessary to ensure that no portion thereof will fail to be tax-deductible to the Company by reason of
Section 280G of the Code or result in an excise tax pursuant to Section 4999 of the Code. The determination of whether any payment
or benefit would (if paid or provided) constitute an excess parachute payment will be made by the Board, in its sole discretion. If a
reduction to the payments otherwise payable under this Agreement or any other arrangement is required pursuant to this Section 5(b),
such reduction shall be made in the following order: (i) first, any future cash payments (if necessary, to zero); (ii) second,
any current cash payments (if necessary, to zero); (iii) third, all non-cash payments (other than equity’ or equity derivative
related payments) (if necessary, to zero); and (iv) fourth, all equity or equity derivative payments; provided that in all events,
such reductions shall be done in a manner consistent with the requirements of Section 409A of the Code, to the extent applicable.

 

(c)            Severance
Conditional upon Release. The payments and benefits described in Section 5(a) are in lieu of, and not in addition to,
any other severance arrangement maintained by the Company. Notwithstanding any provision of this Agreement, the payments described
in Section 5(a) (other than the Accrued Rights) are conditioned on your execution and delivery to the Company of a general
release of all claims against the Company and its Affiliates in a manner consistent with the requirements of the Older Workers
Benefit Protection Act and any other applicable law, and in a form reasonably prescribed by the Company (the “Release”)
and such Release becoming irrevocable within sixty (60) days following the date of termination and (ii) your continued
compliance with the Restrictive Covenants Agreement. The severance benefits described in Section 5(a) (other than the
Accrued Rights) will be paid or begin to be paid or provided within sixty (60) days following your date of termination; provided
that the initial payment of Base Salary continuation shall include a catch-up payment to cover amounts retroactive to the day
immediately following the effective date of your termination of employment. If the severance benefits payable pursuant to
Section 5(a) are deferred compensation subject to the requirements of Section 409A of 

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Five

 

the Code, and if the 60-day
period described herein begins in one taxable year and ends in a second taxable year, such payments shall not commence until the
second taxable year.

 

(d)            Termination
for Cause, upon Disability, or by Voluntary Termination. In the event of termination of your employment by the Company for Cause or
Disability, or your voluntary termination of employment, the Company will pay you the Accrued Rights. The Company shall have no other
obligation to you, including any bonus or severance payments.

 

(e)            Survival
of Certain Provisions. Provisions of this Agreement shall survive any termination if so provided in this Agreement or if necessary
or desirable to accomplish the purposes of other surviving provisions. The obligation of the Company to make payments to you under this
Section 5, and your right to retain such payments, are expressly conditioned upon your continued full performance of your obligations
under the Restrictive Covenants Agreement. Upon termination by either you or the Company, all rights, duties and obligations of you and
the Company to each other shall cease, except as otherwise expressly provided in this Agreement.

 

6.            Definitions.
For purposes of this Agreement, the following definitions apply:

 

“Affiliate” means
any Person that controls, is controlled by or under common control of the Person, with “control” meaning the ownership or
right to vote at least a majority of the equity interests of such Person.

 

“Change in Control”
means (A) the sale, lease, exchange, transfer or other disposition of all or substantially all of the assets of the Company and its
Affiliates, or (B) any sale, merger, consolidation or other business combination that results in the holders of the outstanding voting
securities of the Company immediately prior to such transaction beneficially owning or controlling less than a majority of the voting
securities of the surviving entity immediately thereafter.

 

“Code” means the
Internal Revenue Code of 1986, as amended from time to time.

 

“Disability” means
a condition that, in the judgment of the Board, renders you incapable of performing your duties under this Agreement with or without a
reasonable accommodation.

 

“Person” means
an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust or any other entity or organization,
other than the Company or any of its Affiliates.

 

7.            Conflicting
Agreements. You hereby represent and warrant that your signing of this Agreement and the performance of your obligations under it
will not breach or be in conflict with any other agreement to which you are a party or are bound, and that you are not now subject to
any covenants against competition or similar covenants or any court orders that could affect the performance of your obligations under
this Agreement. You agree that you will not disclose to or use on behalf of the Company any proprietary information of a third party without
that party’s consent.

 

8.            Withholding.
All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company
under applicable law.

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Six

 

9.            Assignment.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement
without your consent to one of its Affiliates or to any Person with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit
of and be binding upon you and the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns.

 

10.          Severability.
If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction,
then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it
is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid
and enforceable to the fullest extent permitted by law.

 

11.          Miscellaneous.
This Agreement sets forth the entire agreement between you and the Company and replaces all prior and contemporaneous communications,
agreements and understandings, written or oral, with respect to the terms and conditions of your employment. This Agreement may not be
modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and an expressly authorized representative
of the Board. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content
of any provision of this Agreement. This Agreement may be executed in two counterparts, each of which shall be an original and all of
which together shall constitute one and the same instrument. This Agreement shall be governed and construed in accordance with the laws
of the Commonwealth of Pennsylvania, without regard to the conflict of laws principles thereof.

 

12.          Notices.
Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United
States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the case of the Company,
to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify
by notice to the other actually received.

 

13.          Section 409A. It
is intended that this Agreement be drafted and administered in compliance with section 409A of the Code, including, but not limited
to, ally future amendments to Code section 409A, and any other Internal Revenue Service or other governmental rulings or
interpretations (together, “Section 409A”) issued pursuant to Section 409A so as not to subject you to payment
of interest or any additional tax under Code section 409A. The parties intend for any payments under this Agreement to either
satisfy the requirements of Section 409A or to be exempt from the application of Section 409A, and this Agreement shall be
construed and interpreted accordingly. Notwithstanding anything in this Agreement to the contrary, all payments to be made upon a
termination of employment under this Agreement will only be made upon a “separation from service” within the meaning of
Section 409A. To the maximum extent permitted under Section 409A, the cash severance benefits payable under this Agreement
are intended to meet the requirements of the short-term deferral exemption under Section 409A and the “separation pay
exception” under Treas. Reg. § 1.409A-1(b)(9)(iii). For purposes of the application of Treas. Reg. §
1.409A-1(b)(4)(or any successor provision), each payment in a series of payments to you will be deemed a separate payment.
Notwithstanding anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to you
constitutes a “deferral of compensation” within 

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Seven

 

the meaning of Section 409A of the Code (i) the amount of
expenses eligible for reimbursement or in-kind benefits provided to you during any calendar year will not affect the amount of
expenses eligible for reimbursement or in-kind benefits provided to you in any other calendar year, (ii) the reimbursements for
expenses for which you are entitled to be reimbursed shall be made on or before the last day of the calendar year following the
calendar year in which the applicable expense is incurred and (iii) the light to payment or reimbursement or in-kind benefits
hereunder may not be liquidated or exchanged for any other benefit.

 

14.          Arbitration.
Any dispute or controversy arising under or in connection with this Agreement or your employment with the Company, other than a claim
for injunctive relief pursuant to the Restrictive Covenants Agreement, shall be settled exclusively by arbitration, conducted before a
single arbitrator in Pittsburgh, Pennsylvania (applying Pennsylvania law) in accordance with the National Rules for the Resolution
of Employment Disputes of the American Arbitration Association then in effect. However, prior to resorting to arbitration, both parties
agree to negotiate in good faith to resolve any such dispute or controversy. The arbiter shall be selected in accordance with the rules of
the American Arbitration Association. The decision of the arbitrator shall be final and binding upon the parties hereto and judgment may
be entered on the arbitrator’s award in any court having jurisdiction. The prevailing party in any such proceeding shall be entitled
to receive from the other party all reasonable attorneys’ fees incurred by such prevailing party and all costs incurred in connection
therewith if and to the extent so awarded by the arbitrator.

 

[remainder of page intentionally left blank]

 

    

     

    

 

Mr. James OBrien

October 7, 2019

Page Eight

 

Please sign this Agreement
in the space provided and return it to me. At the time you sign and return it, and the Company counter-signs it this Agreement will take
effect as a binding agreement between you and the Company on the basis set forth above.

 

	COGNITION THERAPEUTICS, INC.	 	 
	 	 	 
	 	 	 
	 	 	 
	By:	/s/ Kenneth I. Moch	 	By:	/s/ James O’Brien
	Name: 	Kenneth I. Moch	 		James O’Brien
	Title: 	President and Chief Executive Officer	 	 
	 	 	 
	Date signed:          October 7, 2019	 	Date signed:
    October 8, 2019

 

    

     

    

 

EXHIBIT A

 

Restrictive Covenants Agreement

 

    

     

    

 

EMPLOYEE
NON-DISCLOSURE AND

INVENTION ASSIGNMENT AGREEMENT

 

THIS AGREEMENT between Cognition
Therapeutics, Inc. (the “Company”), a Delaware corporation with its principal offices at 2403 Sidney St.,
Suite 261, Pittsburgh, PA 15203 and James M. O’Brien (the “Employee”), an individual residing at the
address set forth on the signature page to this Agreement.

 

Recitals:

 

The parties desire to enter into this Agreement
in connection with the Employee’s employment by the Company.

 

NOW, THEREFORE, in consideration of the employment
of the Employee by the Company and the payment by the Company of compensation to the Employee for services rendered and to be rendered,
and intending to be legally bound hereby, the parties hereto agree as follows:

 

1.            Non-Disclosure
of Confidential Information. The Employee acknowledges that in the course of performing services for the Company, the Employee
may obtain knowledge of the Company’s business plans, products, processes, software, know-how, trade secrets, formulas,
methods, models, prototypes, discoveries, inventions, materials and reagents, improvements, disclosures, customer and supplier
lists, names and positions of employees and/or other proprietary and/or confidential information (collectively, the
 “Confidential Information”). The Employee agrees to keep the Confidential Information secret and confidential and not to
publish, disclose or divulge to any other party, or use for the Employee’s own benefit or to the detriment of the Company,
any Confidential Information without the prior written consent of the Company, whether or not such Confidential Information was
discovered or developed by the Employee. The Employee also agrees not to divulge, publish or use any proprietary and/or
confidential information of others that the Company is obligated to maintain in confidence.

 

2.            Inventions
and Discoveries.

 

(a)           Disclosure. The
Employee shall promptly and fully disclose to the Company, with all necessary detail, all developments, know-how, discoveries,
inventions, improvements, concepts, ideas, formulae, processes and methods (whether copyrightable, patentable or otherwise)
made, received, conceived, acquired or written by the Employee (whether or not at the request or upon the suggestion of the
Company), solely or jointly with others, during the period of the Employee’s engagement by the Company as a consultant
hereunder that (i) relate to any line of business, activity or field of interest or investigation with respect to which the
Employee renders services to the Company or (ii) are otherwise made through the use of the Company’s time, facilities or
materials (all of the foregoing being hereinafter referred to collectively as the “Inventions”).

 

(b)           Assignment
and Transfer. The Employee agrees to assign and transfer to the Company all of the Employee’s right, title and interest in
and to the Inventions, and the Employee further agrees to deliver to the Company any and all drawings, notes, specifications 

 

    

     

    

 

and
data relating to the Inventions,
and to sign, acknowledge and deliver all such further papers, including applications for and assignments of copyrights and patents, and
all renewals thereof, as may be necessary to obtain copyrights and patents for any Inventions in any and all countries and to vest title
thereto in the Company and its successors and assigns and to otherwise protect the Company ’s interests therein.

 

(c)           Power
of Attorney. If the Company is unable, after reasonable effort, to secure the Consultant’s signature on any application
for patent, copyright, trademark or other analogous registration or other documents regarding any legal protection relating to an
Invention, whether because of the Employee’s physical or mental incapacity or for any other reason whatsoever, the Employee
hereby irrevocably designates and appoints each of the President and each Vice President of the Company as the Employee’s
agent and attorney-in-fact, to act for and in the Employee’s behalf and stead to execute and file any such application or
applications or other documents and to do all other lawfully permitted acts to further the prosecution and issuance of patent,
copyright, trademark or other registrations or any other legal protection thereon with respect to an Invention with the same legal
force and effect as if executed by the Employee.

 

(d)           Documentation
and Records. The Employee shall hold in a fiduciary capacity for the benefit of the Company all documentation, disks, programs,
data, records, drawings, manuals, reports, sketches, blueprints, letters, notes, notebooks and all other writings, electronic data,
graphics and tangible information and materials of a secret, confidential or proprietary information nature relating to the Company
or the Company’s business that are in the possession or under the control of the Employee. The Employee agrees that in
connection with any research, development or other services performed for the Company, the Employee will maintain careful, adequate
and contemporaneous written records of all Inventions, which records shall be the property of the Company.

 

3.            Injunctive
Relief. The Employee acknowledges that compliance with this Agreement is necessary to protect the goodwill and other proprietary
interests of the Company. The Employee acknowledges that a breach of this Agreement will result in irreparable and continuing damage
to the Company and its business, for which there will be no adequate remedy at law. The Employee further agrees that in the event of
any breach of this Agreement, the Company and its successors and assigns shall be entitled to injunctive relief and to such
other and further relief and damages as may be proper.

 

4.            No
Right to Employment. It is expressly understood that this Agreement is not intended to define the scope of the Employee’s
employment by the Company or the terms of such employment other than as specifically provided herein. Any such other terms may or
may not be contained in a written agreement. In any event, nothing contained in this Agreement shall be interpreted to create an
employment relationship other than at will.

 

5.            Survival
of Agreement; Binding Nature. It is expressly agreed that the provisions of this Agreement shall survive and apply after the
termination of the Employee’s employment with the Company. This Agreement shall be binding on and inure to the benefit of the
Employee’s executors, administrators or other legal representatives or assigns and on the Company’s successors and
assigns. The Company shall have the right to assign this Agreement without the consent of the Employee.

 

    2

     

    

 

6.            Enforceability.
If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, then such provision shall be deemed to be
modified or restricted to the extent and in the manner necessary to render the same valid and enforceable, or shall be deemed
excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced accordingly to the
maximum extent permitted by law.

 

7.            No
Waiver. No claim or right arising out of a breach or default under this Agreement shall be discharged in whole or in part by a waiver
of that claim or right unless the waiver is in writing and signed by the aggrieved party.

 

8.            Construction.
This Agreement shall be construed and interpreted in accordance with the substantive laws of the Commonwealth of Pennsylvania. This
Agreement supersedes and replaces any existing agreement between the Employee and the Company relating generally to the same subject
matter; and this Agreement may not be modified, in whole or in part, except in writing signed by both of the parties.

 

IN WITNESS WHEREOF, this Agreement has been signed
by the parties as of the date set forth below next to the name of the Employee.

 

	 	 	COGNITION THERAPEUTICS, INC.
	 	 	 	 
	 	 	 	 
	Date:	October 7, 2019	 	By:	/s/ Kenneth I. Moch
	 	 	 
	 	 	Name:        Kenneth I. Moch
	 	 	Title:          President & CEO
	 	 	 
	 	 	 
	Date:	October 8, 2019	 	/s/ James M. O’Brien
	 	 	Employee’s Signature
	 	 	 
	 	 	 
	 	 	James M. O’Brien
	 	 	Name of Employee (please print or type)
	 	 	 
	 	 	 
	 	 	Employee’s Address:
	 	 	20 Hollow Tree Ridge Rd
	 	 	Darien, CT 06828
	 	 	 

 

    3Exhibit 10.24

 

 

Notice of Award

 

	 	
     Multi-Year Funded Research Project Grant

    Department of Health and Human Services 

National Institutes of Health

     

    NATIONAL INSTITUTE ON AGING
	Federal Award Date:    08/14/2016	 

 

Grant Number: 1RF1AG054176-01

FAIN: RF1AG054176

 

Principal Investigator(s):

SUSAN M CATALANO, PHD

 

Project Title: Phase 1b first-in-patient safety trial for CT1812,
a novel Alzheimer’s synaptic protection therapeutic

 

Catalano, Susan

Chief Science Officer 

2403 Sidney Street

Suite 261

Pittsburgh, PA 152035118

 

Award e-mailed to: scatalano@cogrx.com

 

Period Of Performance:

Budget Period: 08/15/2016 - 07/31/2018

Project Period: 08/15/2016 - 07/31/2018

 

Dear Business Official:

 

The National Institutes of Health hereby awards a grant in the amount
of $2,410,669 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to COGNITION THERAPEUTICS,
INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the
requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

 

Acceptance of this award including the “Terms and Conditions”
is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document about research
supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this
publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number RF1AG054176. The
content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes
of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance
to allow for coordination.

 

Award recipients must promote objectivity in research by establishing
standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free
from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation
at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation
does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the
NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

    Page-1

     

    

 

If you have any questions about this award, please contact the individual(s)
referenced in Section IV.

 

Sincerely yours,

 

TRACI LAFFERTY

Grants Management Officer

NATIONAL INSTITUTE ON AGING

 

Additional information follows

 

    Page-2

     

    

 

SECTION I - AWARD DATA - 1RF1AG054176-01

 

	Award Calculation (U.S.  Dollars)	 	 	 
	Salaries and Wages	 	$	200,532	 
	Personnel Costs (Subtotal)	 	$	200,532	 
	Other	 	$	1,728,003	 
	 	 	 	 	 
	Federal Direct Costs	 	$	1,928,535	 
	Federal F&A Costs	 	$	482,134	 
	Approved Budget	 	$	2,410,669	 
	Total Amount of Federal Funds Obligated (Federal Share)	 	$	2,410,669	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	2,410,669	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	2,410,669	 

 

	SUMMARY TOTALS FOR ALL YEARS	 
	YR	 	 	THIS AWARD	 	 	CUMULATIVE TOTALS	 
	1	 	 	$	2,410,669	 	 	$	2,410,669	 

 

Fiscal Information:

	CFDA Name:	Aging Research
	CFDA Number:	93.866
	EIN:	1134365359A1
	Document Number:	RAG054176A
	PMS Account Type:	P (Subaccount)
	Fiscal Year:	2016

 

	IC	 	CAN	 	 	2016	 
	AG	 	 	8013663	 	 	$	2,410,669	 

 

NIH Administrative Data:

PCC: 3CCCTLR / OC: 414A / Released: LAFFERTYT 08/11/2016

Award Processed: 08/14/2016 08:10:03 AM

 

SECTION II - PAYMENT/HOTLINE INFORMATION
- 1RF1AG054176-01

 

For payment and HHS Office of Inspector General Hotline information,
see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

SECTION III - TERMS AND CONDITIONS
- 1RF1AG054176-01

 

This award is based on the application submitted to, and as approved
by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

 

		a.	The grant program legislation and program regulation cited in this
                                            Notice of Award.

		b.	Conditions on activities and expenditure of funds in other statutory
                                            requirements, such as those included in appropriations acts.

		c.	45 CFR Part 75.

		d.	National Policy Requirements and all other requirements described
                                            in the NIH Grants Policy Statement, including addenda in effect as of the beginning date
                                            of the budget period.

		e.	Federal Award Performance Goals: As required by the periodic report
                                            in the RPPR or in the final progress report when applicable.

		f.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

    Page-3

     

    

 

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm
for certain references cited above.)

 

Research and Development (R&D): All awards issued by
the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part § 75.2. As
such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA).
The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may
have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is
classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee
is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

 

An unobligated balance may be carried over into the next budget period
without Grants Management Officer prior approval.

 

This grant is excluded from Streamlined Noncompeting Award Procedures
(SNAP). MULTI-YEAR FUNDED AWARD: This is a multi-year funded award. A progress report is due annually on or before the anniversary
of the budget/project period start date of the award, in accord with the instructions posted at: http://grants.nih.gov/grants/policy/myf.htm.

 

This award is subject to the requirements of 2 CFR Part 25 for institutions
to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award
Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm
for the full NIH award term implementing this requirement and other additional information.

 

This award has been assigned the Federal Award Identification Number
(FAIN) RF1AG054176. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

 

Based on the project period start date of this project, this award
is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions
that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

 

In accordance with P.L. 110-161, compliance with the NIH Public Access
Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

 

This award provides support for one or more clinical trials. By law
(Title VIII, Section 801 of Public Law 110-85), the “responsible party” must register “applicable clinical trials”
on the ClinicalTrials.gov Protocol Registration System Information Website. NIH encourages registration of all trials whether
required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials fdaaa/

 

This award represents the final year of the competitive segment for
this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: http://grants.nih.gov/grants/policy/policy.htm#gps.

 

A final expenditure Federal Financial Report (FFR) (SF 425) must be
submitted through the eRA Commons (Commons) within 120 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1
Financial Reports, http://grants.nih.gov/grants/policy/policy.htm#gps, for additional information on this submission requirement.
The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no
discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) quarterly cash transaction data.
A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards to foreign entities and
to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards that do not require a final
FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial closeout, if a grantee
fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown level. If the grantee
submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final expenditure FFR and
the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result in disallowed costs.

 

    Page-4

     

    

 

A Final Invention Statement and Certification form (HHS 568), (not
applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date.
The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm. This paragraph does not apply to Training grants,
Fellowships, and certain other programs—i.e., activity codes C06, R13, R25, S10.

 

Unless an application for competitive renewal is submitted, a final
progress report must also be submitted within 120 days of the expiration date. Instructions for preparing a Final Progress Report are
at: http://grants.nih.gov/grants/funding/finalprogressreport.pdf. Any other specific requirements set forth in the terms and conditions
of the award must also be addressed in the final progress report. Institute/Centers may accept the progress report contained in competitive
renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC for IC- specific policy regarding acceptance of
a progress report contained in a competitive renewal application in lieu of a separate final progress report.

 

NIH strongly encourages electronic submission of the final progress
report and the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission
as indicated below.

 

Email: The final progress report and final invention statement may
be e-mailed as PDF attachments to: NIHCloseoutCenter@mail.nih.gov.

 

Hard copy: Paper submissions of the final progress report and the
final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-4802304, or
mailed to:

 

National Institutes of Health

Office of Extramural Research

Division of Central Grants Processing

Grants Closeout Center

6705 Rockledge Drive

Suite 5016, MSC 7986

Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)

Bethesda, MD 20817 (for other courier/express deliveries only)

 

NOTE: If this is the final year of a competitive segment due to the
transfer of the grant to another institution, then a Final Progress Report is not required. However, a final expenditure FFR is required
and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should
be sent directly to the assigned Grants Management Specialist.

 

In accordance with the regulatory requirements provided at 45 CFR
75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement
contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management
(SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached
final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings.
Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee
Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR
Part 75. This term does not apply to NIH fellowships.

 

    Page-5

     

    

 

Treatment of Program Income:

Additional Costs

 

SECTION IV - AG Special Terms and
Conditions - 1RF1AG054176-01

 

Restriction: This award restricts all funds requested for F&A
that are in excess of 10% of salaries and wages, $462,081 is restricted pending the negotiation of an F&A rate(s). These restricted
funds may not be used for any purpose without the prior approval of the grants management official. If the rate(s) negotiated is(are)
lower than originally estimated/funded, this award amount may be revised downward.

 

Restriction: Recruitment of participants cannot be initiated
until the NIA program staff, the IRB and the DSMB have approved the protocol and data and safety monitoring plan.

 

Funding for this award has been provided by Alzheimer’s Disease
Initiative funds.

 

The progress report for this multi-year funded (MYF) award is due
annually on or before the anniversary of the budget/project period start date of the award and must be submitted via the eRA Commons.
Additional information on submission requirements and directions can be found at http://grants.nih.gov/grants/policy/myf.htm.

 

None of the funds in this award shall be used to pay the salary of
an individual at a rate in excess of the current salary cap. Therefore, this award and/or future years are adjusted accordingly, if applicable.
Current salary cap levels can be found at the following URL: http://grants.nih.gov/grants/policy/salcap summary.htm.

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for the negotiation,
award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official
is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project
administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the
Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: Robin Laney

Email: laneyr@nia.nih.gov Phone: 301-496-1472 Fax: 301-402-3672

 

Program Official: Laurie M. Ryan

Email: ryanl@nia.nih.gov Phone: 301.496.9350 Fax: 301-496-1494

 

SPREADSHEET SUMMARY

GRANT NUMBER: 1RF1AG054176-01

 

INSTITUTION: COGNITION THERAPEUTICS, INC.

 

	Budget	 	Year 1	 
	Salaries and Wages	 	$	200,532	 
	Personnel Costs (Subtotal)	 	$	200,532	 
	Other	 	$	1,728,003	 
	TOTAL FEDERAL DC	 	$	1,928,535	 
	TOTAL FEDERAL F&A	 	$	482,134	 
	TOTAL COST	 	$	2,410,669	 

 

	Facilities and Administrative Costs	 	Year 1	 
	F&A Cost Rate 1	 	 	25	%
	F&A Cost Base 1	 	$	1,928,535	 
	F&A Costs 1	 	$	482,134	 

 

    Page-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]